UnknownNot Applicable

Effect of Covid 19 Infection on Fetomaternal Outcome

Egypt50 participantsStarted 2021-10-10

Plain-language summary

The novel coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was discovered for the first time in December 2019 in Wuhan (China) and the disease it causes is called coronavirus disease 2019 (COVID-19). Now, this pandemic is rapidly spreading all over the world. Pregnant have higher rates of COVID-19, associated with hospitalizations, and severe in-hospital outcomes. Immune responses may have a potential role in the diagnosis, treatment, and prognosis of patients with COVID-19. So we need of identifying biomarkers for disease severity and progression.

Who can participate

Age range18 Years – 40 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Positive RT-PCR nasopharyngeal swab is taken (even if the result became available after labor);
✓. Positive rapid antigen test performed before labor
✓. Chest computed tomography (CT) scan performed before labor showing changes consistent with pneumonitis secondary to SARS-CoV-2 infection;
✓. Positive pre-labor immunoglobulin G or immunoglobulin M antibody test; or
✓. Clinical diagnosis made before labor (in the absence of negative RT-PCR swab results).

Exclusion criteria

✕. Healthy individuals:
✕. Acute or chronic infectious disease,
✕. And any medication with known influence on immunological factors.

What they're measuring

First, second and third trimester fetomaternal complications.

Timeframe: 3 months

fetal distress

Timeframe: 3 months

Trial details

NCT IDNCT05160649

SponsorFayoum University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-06

View on ClinicalTrials.gov More COVID-19 trials